Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $18.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 174.39% from the company’s previous close.

Separately, Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, March 20th.

Coya Therapeutics Stock Down 1.2 %

Shares of COYA stock opened at $6.56 on Tuesday. The stock has a 50-day simple moving average of $6.19 and a 200 day simple moving average of $6.42. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The stock has a market capitalization of $109.72 million, a P/E ratio of -10.09 and a beta of 0.49.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, sell-side analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $59,000. Jane Street Group LLC bought a new position in Coya Therapeutics during the fourth quarter worth $74,000. Northern Trust Corp grew its stake in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after buying an additional 3,099 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $401,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.